Financial Support

Contact us directly at:
866.547.0644 8 AM to 8 PM ET, Monday through Friday
To ask about distribution, please email:

Providing individualized support to help eligible patients get access to KINERET

Our team of experts is here to help with prescription delivery, treatment administration, insurance reimbursement, financial assistance, and answers to some KINERET-related questions.

Contact us directly at:
866.547.0644 8 AM to 8 PM ET, Monday through Friday To ask about distribution, please email:
Icon of money dropping into a hand

Financial Assistance and Reimbursement

KINERET Case Managers can help you and your patients navigate access solutions.

Financial assistance programs:
  • Enroll your patients in the Copay Program to see if they qualify. Eligible commercially insured patients may receive up to $13,000 per year to lower out-of-pocket costs to as little as $0 per month.* Click here to enroll your patients
  • A patient assistance program that can help eligible uninsured and underinsured patients access KINERET free of charge†

*Patient must be a resident of the US or Puerto Rico. Patient must be commercially insured. There are no income requirements to participate in the program. Patient is not enrolled in any government, state, or federally funded prescription program, including Medicare, Medicaid, Medigap, VA, DOD, or TRICARE.
 †Patients must be US citizens or legal residents under the care of a licensed practicing healthcare provider and prescribed KINERET. Other terms and conditions apply.

Case Managers can also help with:
  • Benefits investigations
  • Insurance coverage verification
  • Prior authorization support
  • Appeals support
As little as $0 copay icon
Icon of 3 figures with circles above their heads

Direct Support for Your Patients

Patients can sign up for KINERET® On TRACK™ Guidance to receive extra support.

KINERET On TRACK Guidance offers:

  • Personalized communications from our team of experts to help your patients get started
  • Educational materials that help them know what to expect
  • Online resources packed with useful information
Nurse icon

Treatment Administration Assistance

KINERET Trained Nurses can help your patients understand how to use KINERET, with your direction.

Nurse services include:

  • One-on-one injection training and in-home or virtual visits
  • Tips to help address common injection site reactions
  • Advice on injection site rotation and tracking
  • Helpful insights on issues from medication storage to travel
Prescription delivery truck icon

KINERET Delivery Service

KINERET Pharmacy Specialists will deliver your patient's prescriptions right to their doors. The first time. And every time.

Pharmacy Specialist services include:

  • Prescription delivery directly to patients' homes
  • Free sharps containers and needle clippers
  • Refill reminders
  • Emergency shipments
  • Information about KINERET
PREVIOUS:   Dosing Calculator
NEXT:   Resources
Indications and Important Safety Information
INDICATIONS
KINERET® (anakinra) is an interleukin-1 receptor antagonist indicated for:
Rheumatoid Arthritis (RA)
  • Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease-modifying antirheumatic drugs (DMARDs)
Cryopyrin-Associated Periodic Syndromes (CAPS)
  • Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
  • Treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
IMPORTANT SAFETY INFORMATION
  • KINERET is contraindicated in patients with known hypersensitivity to E. coli–derived proteins, KINERET, or to any components of the product
  • In RA, discontinue use if serious infection develops. In KINERET-treated NOMID or DIRA patients, the risk of a disease flare when discontinuing KINERET treatment should be weighed against the potential risk of continued treatment. Do not initiate KINERET in patients with active infections
  • Use in combination with Tumor Necrosis Factor (TNF)-blocking agents is not recommended
  • Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported. Patients with DIRA may have an increased risk of allergic reactions, particularly in the first several weeks after starting KINERET treatment
  • The impact of treatment with KINERET on active and/or chronic infections and the development of malignancies is not known
  • Live vaccines should not be given concurrently with KINERET
  • Neutrophil counts should be assessed prior to initiating KINERET treatment, and while receiving KINERET, monthly for 3 months, and thereafter quarterly for a period up to 1 year

RA: Most common adverse reactions (incidence ≥ 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu-like symptoms, and abdominal pain

NOMID: The most common AEs during the first 6 months of treatment (incidence > 10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis

DIRA: The most common AEs are upper respiratory tract infections, rash, pyrexia, influenza-like illness, and gastroenteritis

  • A higher rate of serious infections has been observed in RA patients treated with concurrent KINERET and etanercept therapy than in patients treated with etanercept alone. Use of KINERET in combination with TNF-blocking agents is not recommended
  • KINERET is indicated for use in pediatric patients with NOMID and DIRA
  • Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly
  • KINERET is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function
Please see full Prescribing Information.